



8-2-04

16534
GFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1653
BAR-OR et al.) Examiner: LUKTON, David
Serial No.: 09/678,202)
Filed: September 29, 2000)
Atty. File No.: 4172-3)
For: "METAL-BINDING COMPOUNDS) Express Mail Label: EV510769905US
AND USES THEREFOR") 08/04/2004 NROCHAI 00000012 09678202

**INFORMATION DISCLOSURE
STATEMENT**

Mail Stop: Amendments
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

01 FC:1806

180,00 0P

Siri

The references cited on attached Form PTO-1449 are being called to the attention of the Examiner.

- Copies of the cited references are enclosed herewith.
 - Copies of the cited U.S. patents and/or U.S. patent application publications are not enclosed in accordance with the waiver dated July 11, 2003, whereby patent applications filed after June 30, 2003 and international applications that have entered the national stage under 35 U.S.C. § 371 after June 30, 2003 need not submit copies of U.S. patents and U.S. patent application publications.
 - Are not enclosed, in accordance with 37 C.F.R. 1.98(d), because the references were submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____ filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120.
 - To the best of applicants' belief, the pertinence of the foreign-language references are believed to be summarized in the attached English abstracts and in the figures, although applicants do not necessarily vouch for the accuracy of the translation.
 - Examiner's attention is directed to the following co-pending application(s) for which priority is not being claimed, copies are being submitted herewith:

Serial No. 16/373,374 Filed February 13, 2002, US-2003-0088488 A1 (Att'y. Dkt. No. 4172-3-2)

Serial No. 10/188,188 Filed June 27, 2002, US-2003-0150189-A1, (Att'y. Dkt# No. 4172-3-3)

- Examiner's attention is directed to the following co-pending application(s), to which the current application claims priority, copies of at least the claims for such pending application are provided or have been provided:

Serial No. _____ filed _____ (Atty. Dckt. No. _____)

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

<input type="checkbox"/>	<p>37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith satisfies one of the following conditions ("X" indicates satisfaction):</p> <ul style="list-style-type: none"><input type="checkbox"/> Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or<input type="checkbox"/> Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or<input type="checkbox"/> Before the mailing date of a first Office Action on the merits, or<input type="checkbox"/> Before the mailing of a first Office action after the filing of a Request for Continued Examination (RCE) under 37 CFR 1.114. <p>Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.</p>
<input checked="" type="checkbox"/>	<p>37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions:</p> <ol style="list-style-type: none">(1) a final action under 37 C.F.R. 1.113 or(2) a notice of allowance under 37 C.F.R. 1.311, or(3) an action that otherwise closes prosecution in the application. <p>This Information Disclosure Statement is accompanied by:</p> <ul style="list-style-type: none"><input type="checkbox"/> A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.<li style="text-align: center;">OR<input checked="" type="checkbox"/> A check in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account No. 19-1970.
<input type="checkbox"/>	<p>37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c).</p> <ul style="list-style-type: none"><input type="checkbox"/> This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e)<li style="text-align: center;">AND<input type="checkbox"/> Applicants hereby requests consideration of the reference(s) disclosed herein. Enclosed is the fee in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit Account No. 19-1970. Please credit any overpayment or charge any underpayment to Deposit Account No. 19-1970.Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.



Certification (37 C.F.R. 1.97(e))
(Applicable only if checked)

The undersigned certifies that:

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).
- A copy of the communication from the foreign patent office is enclosed.

OR

- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).

Respectfully submitted,

SHERIDAN ROSS, P.C.

By: Mary B. Smith

Mary B. Smith
Registration No. 43,512
1560 Broadway, Suite 1200
Denver, CO 80202-5141
TELEPHONE: 303-863-2975
FAX: 303-863-0223

Date: July 30, 2004
J:\4172\3\IDS-008.wpd

SHEET 1 OF 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4172-3	SERIAL NO. 09/678,202
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANT BAR-OR et al.	
		FILING DATE September 29, 2000	GROUP ART 1653

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
1	2003/0130185	7/10/2003	Bar-Or et al.	514	12	6/27/2002
2	6,583,182	6/24/2003	Winchell et al.	514	648	
3	2003/0060408	3/27/2003	Bar-Or et al.	514	12	2/13/2002
4	6,264,966	7/24/2001	Winchell et al.	424	401	
5	4,323,558	4/6/1982	Nelson	424	164	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	6	WO 02/43722	6/6/2002	PCT	A61K	31/132		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

7	Cameron et al.; "Neurovascular Dysfunction in Diabetic Rats. Potential Contribution of Autoxidation and Free Radicals Examined Using Transition Metal Chelating Agents"; <i>J.Clin Invest.</i> ; August 1995; 96(2):1159-63; 1 p. Abstract from NCBI PubMed; PMID: 7635953
8	Love et al.; "Nerve Function and Regeneration in Diabetic and Galactosaemic Rats: Antioxidant and Metal Chelator Effects"; <i>Eur J Pharmacol.</i> ; October 24, 1996; 314(1-2):33-9; 1 p. Abstract from NCBI PubMed; PMID: 8957216
9	Yoshii et al.; "The Copper-Chelating Agent, Trentine, Suppresses Tumor Development and Angiogenesis in the Murine Hepatocellular Carcinoma Cells"; <i>Int J Cancer.</i> ; December 15, 2001; 94(6):768-73; 1 p. Abstract from NCBI PubMed; PMID: 11745476

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	